saplin

Tata India Pharma & Healthcare Fund

Tata India Pharma & Healthcare Fund (Direct, Growth): saplin Score 6.0/10 (Neutral) among 14 Sectoral/Thematic funds. 3Y return 19.1% a year vs 21.9% category median, expense ratio 1.09%. Uneven returns hold this fund back. NAV ₹39.89 on 11 Nov 2026.

Loading the full analysis…

Questions about Tata India Pharma & Healthcare Fund

What is the expense ratio of Tata India Pharma & Healthcare Fund?

The Direct plan's total expense ratio is 1.09% a year, against a median of 1.04% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

Who manages Tata India Pharma & Healthcare Fund?

Rajat Srivastava (since 16 Sept 2024).

What are the top holdings of Tata India Pharma & Healthcare Fund?

Sun Pharmaceutical Industries 7.89%, Abbott India 5.66%, Divi's Laboratories 5.41%, Healthcare Global Enterprises 5.25%, Dr. Reddy's Laboratories 5.14% of the portfolio, as of 31 Oct 2026.

What returns has Tata India Pharma & Healthcare Fund given?

1 year: 11.3% (category median 21.9%); 3 years: 19.1% a year (category median 21.9%); 5 years: 15.9% a year (category median 16.8%). Past returns do not predict future ones.

How big is Tata India Pharma & Healthcare Fund?

About ₹1,534 cr (AMFI's average for the latest quarter).

How does Tata India Pharma & Healthcare Fund score?

6.0 out of 10 (Neutral) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.

More on Tata India Pharma & Healthcare